---
schema_version: "secwatch.filing_event.v1"
accession: "0001856725-26-000003"
form_type: "8-K"
ticker: "RANI"
cik: "0001856725"
company_name: "Rani Therapeutics Holdings, Inc."
filed_at: "2026-06-29T22:54:48+00:00"
generated_at: "2026-06-30T10:05:31.210546+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rani Therapeutics appoints Nicholas Maestas as CFO, approves 2026 Equity Inducement Plan

## Summary
- Nicholas Maestas appointed CFO effective June 29, 2026, succeeding Svai Sanford.
- Maestas previously CFO of Tempest Therapeutics; base salary $500,000, target bonus 75%.
- Maestas receives inducement option for 2,000,000 shares vesting over 4 years.
- Board approved 2026 Equity Inducement Plan reserving 5,500,000 shares for new hires.
- Plan allows inducement grants under Nasdaq Rule 5635(c)(4) without stockholder approval.

## SEC filing metadata
- accession: 0001856725-26-000003
- form_type: 8-K
- ticker: RANI
- cik: 0001856725
- company_name: Rani Therapeutics Holdings, Inc.
- filed_at: 2026-06-29T22:54:48+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1856725/000185672526000003/0001856725-26-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1856725/000185672526000003/rani-20260624.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001856725-26-000003
- JSON: https://secwatch.observer/filing/0001856725-26-000003.json
- Plain text: https://secwatch.observer/filing/0001856725-26-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.